I
Innolake Biopharm
A clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases
About Innolake Biopharm
Innolake Biopharm is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, with a business operation center in Shanghai. Founded in December 2020 by Dr. Mingde Xia and Robert Chen, the company develops innovative medicines for cancer and autoimmune diseases. Its R&D pipeline spans antibody-drug conjugates (ADCs), biologics and small-molecule programs built on proprietary technology platforms, with more than ten drug candidates in development, two of which have entered the clinical stage. Innolake combines in-house research and development with strategic partnerships with multinational pharmaceutical and biotech companies, including collaborations with WuXi Biologics and Ellipses Pharma on ADC development. The company serves patients with unmet medical needs in oncology and immunology across the Chinese and global biopharmaceutical markets.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $14M | $55M | WuXi Biologics · Zhongbo Juli · Hangzhou Heda Industry Fund | ↗ |
| SEEDOther financing | Jan 2021 | $41M | $165M | CDH Investments · Huagai Capital · WuXi Biologics | ↗ |
Growth signals
Latest recorded traffic for Innolake Biopharm is 370 monthly website visits, down 50.7% over the last three months. Innolake Biopharm's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Innolake Biopharm in the Hangzhou ecosystem
The Innolake Biopharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CDH Investments
Huagai Capital
WuXi Biologics
Series A2 investors entered at this stage
- ZJZhongbo Juli
- HFHangzhou Heda Industry Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Innolake Biopharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innolake Biopharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









